Leukemia and Lymphoma

The AJMC^® Leukemia & Lymphoma compendium is a comprehensive resource for clinical news and expert insights for the blood cancers and their treatments.

Latest News

3D illustration showing abundant lymphoblasts in blood | Image credit: Dr_Microbe - stock.adobe.com

Obe-Cel Is Effective Irrespective of Age in Relapsed/Refractory B-ALL

By Caroline Seymour

July 14th 2025

Obecabtagene autoleucel showed over 70% response rates in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), demonstrating efficacy across all age groups in recent trials.

Child standing on scale | Image Credit: Protsenko Dmitriy - stock.adobe.com

Obesity at Cancer Diagnosis Linked to Worse Survival Outcomes in Pediatric Patients

By Brooke McCormick

January 13th 2025

Hodgkin lymphoma | Image credit: Dr_Microbe - stock.adobe.com

BrECADD Regimen Reaches “Unprecedently High” PFS for Patients With Hodgkin Lymphoma

By Laura Joszt, MA

June 18th 2024

FDA Approved - chrisdorney - stock.adobe.com.jpg

Zanubrutinib Plus Obinutuzumab Granted Accelerated FDA Approval for R/R Follicular Lymphoma

By Rose McNulty

March 7th 2024

Red Blood Cells - Design Cells stock.adobe.com

alloHSCT Yields Benefits in R/R AML Regardless of Leukemia Burden

December 22nd 2023

Continuing Medical Education

August 15th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

August 15th 2025

ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care

1.0 Credit / Oncology, Hematology, Hematologic Cancer

August 15th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

August 15th 2025

Overcoming Operational and Clinical Barriers in Multiple Myeloma: Managed Care Strategies for Antibody-Based Regimens

1.5 Credits / Hematologic Cancer, Hematology, Oncology

August 15th 2025

Exploring Therapeutic Advances in Myelofibrosis and Key Considerations for Effective Management

1.5 Credits / Oncology, Hematology

More News

May 30th 2015

Choosing Ideal Lymphoma Regimens in the Clinic

Surabhi Dangi-Garimella, PhD

On the first day at the annual meeting of the American Society of Clinical Oncology in Chicago, physicians introduced some of the newer agents currently available to treat lymphoma and described their experience with these agents during the session, "Incorporating Novel Agents into Lymphoma Therapy: Value in Everyday Practice."

March 23rd 2015

Forcing Leukemia Cells to Behave

During laboratory experiments, while growing these leukemic cells, the authors observed that some of the cancer cells in culture were changing shape and size into what looked like macrophages. Subsequent experiments confirmed that by manipulating some of the transcription factors, these human cancer cells could be transformed into macrophages, which can engulf and digest cancer cells and pathogens.

March 17th 2015

Encouraging Results from Imbruvica in CLL and Small Lymphocytic Lymphoma

Improved survival without disease progression prompted independent reviewers to unblind the study comparing Imbruvica against a placebo, in combination with bendamustine and rituximab.

March 11th 2015

NICE Recommends Gazyvaro for Treatment-Naive CLL Patients

The recommendation has not come easy for Roche. Back in October 2014, NICE had rejected Gazyravo based on inconsistencies in the filing, which were then addressed by the drug manufacturer. Subsequently, NICE struck a deal with Roche to provide the drug to NHS at a reduced price.

March 5th 2015

AbbVie to Buy Oncology Company Pharmacyclis

AbbVie will spend about $21 billion to buy leukemia drugmaker Pharmacyclics in its first major deal attempt since walking away from a $55 billion takeover of Shire last fall.

February 24th 2015

Study Results Could Improve Quality of Life in Pediatric ALL

The study, conducted in 2 separate patient cohorts at St. Jude Children's Hospital and the Children's Oncology Group and published in the The Journal of the American Medical Association, found that children with gene variants in the CEP72 gene were more sensitive to vincristine-induced peripheral neuropathy.

January 20th 2015

ASCO Declares CLL Regimens Cancer

In it's report, "Clinical Cancer Advances 2015: ASCO's Annual Report on Progress Against Cancer," published in the Journal of Clinical Oncology, 4 newly approved treatments for CLL were predicted to have a dramatic impact on patients with the disease.

January 19th 2015

Ibrutinib Demonstrates Significant Responses for Patients With Hard-to-Treat CLL/SLL, Phase 2 Data Show

Mary K. Caffrey

December 12th 2014

Nashville Star Charles Esten Shares Personal Experience in Battling Rare Blood Disease

Actor and singer Charles Esten, whose daughter was diagnosed with leukemia when she was 2-and-a-half, shares the challenging and painful experiences of battling the disease.

Session on Survivorship Outlines Surveillance Strategies in Non-Hodgkin Lymphoma

December 8th 2014

Session on Survivorship Outlines Surveillance Strategies in Non-Hodgkin Lymphoma

At an education session at the American Society of Hematology Annual Meeting, Christopher R. Flowers, MD, MS, discussed current thinking in the use of routine imaging for patients who have achieved a long-term complete response in non-Hodgkin lymphoma.

December 3rd 2014

Amgen's Blincyto Approved for B-Cell ALL

Blincyto, which was considered a promising immunotherapy with a novel mechanism of action, was approved 5 months prior to its PDUFA date.

November 30th 2014

Genes Could Predict

The NIH-funded study, published in the New England Journal of Medicine, identified mutations that are harbored early and could be potential early-onset biomarkers for detection.

October 30th 2014

EMA Grants Orphan Status to Kiadis Pharma's Immuno-oncology Molecule

The European Medicines Agency granted an orphan status to ATIR, a T-cell immunotherapy-based medicinal product being developed to treat blood cancers.

October 21st 2014

In the Literature: New Lead in Treating ALL

The paper, published in Nature, has identified a "switch" that can be inhibited to restrict tumor growth.

October 16th 2014

Exciting Clinical Results With Novartis' Leukemia Immune Therapy

The regimen, based on reprogramming the patient's immune T cells to attack the cancer cells, led to the disappearance of cancer in 90 percent of patients, according to a study published in the New England Journal of Medicine.

October 13th 2014

BMS' PD-1 Inhibitor, Nivolumab, to be Evaluated With Jansenn's Ibrutinib in NHL

Opdivo (nivolumab), which was approved in Japan in July 2014, is being globally developed for evaluation in non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma (RCC), head and neck cancer, glioblastoma, as well as NHL.

October 11th 2014

Immuno-oncology Innovation From Amgen Set for Priority Review

The new BiTE antibody technology developed by the company can simultaneously engage 2 different targets, which can help recruit T-cells to malignant cells, and will be evaluated in ALL patients.

October 10th 2014

Velcade Approved For Treatment-NaÃ¯ve Mantle Cell Lymphoma Patients

The approval extends the use of bortezomib beyond relapsed and refractory patients.

October 6th 2014

Vosaroxin Fails in Phase 3 AML Trials in the Elderly

Sunesis Pharmaceuticals announced the failure of a phase 3 study Monday morning. The company's experimental drug vosaroxin did not extend survival of elderly patients with advanced acute myeloid leukemia compared to a placebo.

October 3rd 2014

Value Discussion Reemerges at NICE: Roche's Gazyvaro Rejected

Following Kadcyla, NICE has now rejected another drug from Roche: Gazyvaro for CLL, citing ambiguities in the company's filing and the high cost.

July 29th 2014

Gilead's Idelalisib Receives CHMP Recommendation for Treating CLL and FL

The recommendation to the EMA came soon after Zydiga (idelalisib) was approved in the US.

July 28th 2014

FDA Approves Imbruvica for Treating Chromosome 17-Deletion CLL Patients

New trial data confirms its use as standard therapy for CLL.

July 28th 2014

Study Reports Exclusion from Trials Responsible for Poor Outcomes in HIV-Positive Cancer Patients

HIV-positive individuals are not usually enrolled in clinical trials, resulting in a knowledge-gap on their treatment options.

July 23rd 2014

Gilead's Idelalisib Approved for CLL and Lymphoma

The drug has been approved for use in patient's with relapsed disease.

July 3rd 2014

FDA approves Beleodaq to treat rare, aggressive form of non-Hodgkin lymphoma

July 1st 2014

Amgen's Blinatumomab Receives Breakthrough Designation in ALL

Breakthrough Designation Reinforces Significant Unmet Need in the Treatment of This Highly Aggressive Cancer

June 30th 2014

CT Scan Could Double the Risk of Cancers in NHL Patients

Patients with non-Hodgkin's lymphoma who have received 8 or more CT scans have a 2-fold risk for secondary primary malignancies, new research shows.

June 5th 2014

Carl June Receives 2014 Taubman Prize for his Pioneering Work in Adoptive Cell Transfer

A physician-scientist who developed a personalized immunotherapy for leukemia using patients' own T cells is the recipient of the 2014 Taubman Prize for Excellence in Translational Medical Science, awarded by the A. Alfred Taubman Medical Research Institute at the University of Michigan Medical School.

Velcade: A Progress Report in Various Cancers

June 1st 2014

Velcade: A Progress Report in Various Cancers

Velcade (bortezomib), developed by Millenium Pharmaceuticals, is a proteasome inhibitor that is currently approved for the treatment of multiple myeloma and relapsed mantle cell lymphoma. Several abstracts were presented at the annual meeting of the American Society of Clinical Oncology this year for its use in other indications.

Encouraging Results in Leukemia from a BCL-2 Inhibitor

May 31st 2014

Encouraging Results in Leukemia from a BCL-2 Inhibitor

ABT-199, the result of a collaboration between AbbVie and Genentech, is a selective, potent, orally available BCL-2 inhibitor. The drug is being developed in collaboration by the two companies for acute myelogenous leukemia and chronic lymphocytic leukemia (CLL).

...

13 14 15 16 17 18 19 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions